SCLX · Scilex Holding Co · Metrics
$2.09
+0.04 (+1.95%)
At close · Oct 28
View the 10-Q filed Aug 14, 2026
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“management has concluded that the aforementioned conditions, among other things, raise substantial doubt about the Company's ability to continue as a going concern for one year after the date the unaudited condensed consolidated financial statements are issued.”View the 10-Q filed Aug 14, 2026
Customer concentration
— top 4 customers 96% of revenue
4 customers — 96% of revenue (the three months ended June 30, 2026)
“The Company had four customers during the three and six months ended June 30, 2026, each of which individually generated 10% or more of the Company’s total revenue. These customers accounted for 96% and 95% of the Company’s revenue for the three and six months ended June 30, 2026, respectively, individually ranging from 22% to 27% and 19% to 27%.”
4 customers — 95% of revenue (the six months ended June 30, 2026)
“The Company had four customers during the three and six months ended June 30, 2026, each of which individually generated 10% or more of the Company’s total revenue. These customers accounted for 96% and 95% of the Company’s revenue for the three and six months ended June 30, 2026, respectively, individually ranging from 22% to 27% and 19% to 27%.”
4 customers — 80% of receivables (As of June 30, 2026)
“As of each of June 30, 2026 and 2025, these customers represented 80% and 99% of the Company’s outstanding accounts receivable, individually ranging between 16% and 37%, and 19% and 30% for respective periods.”
Market Cap
$17.41M
Shares
8.49M
Volume · Oct 28
17.03K
Avg daily vol (3M)
44.59K
SCLX metrics
57 of 122 screener metrics currently available.
Market overview
2 metricsShare price
$2.09
Market cap
$17.41M
Price action
20 metricsPrice change (1W)
-19.0%
Price change (30D)
-54.3%
Price change (3M)
-69.9%
Price change (6M)
—
Price change (YTD)
—
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
87.8%
Annualized volatility (3M)
65.4%
Beta
—
RSI (14D)
14.3
Price vs SMA 50
-53.4%
Price vs SMA 200
—
Avg volume (3M)
46,056
Relative volume
2.2
Average dollar volume
$228,995
Company
3 metricsSector
Healthcare
Industry
Drug Manufacturers - General
Shares outstanding
8.49M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
0.6×
reciprocal yield 165.4%
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-2,431.0%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
—
Profitability
9 metricsGross margin
—
Operating margin
-1,136.4%
Trailing 12 months
Net margin
-1,469.8%
Gross profit (TTM)
$50.91M
Operating profit (TTM)
−$359.19M
Net income (TTM)
−$464.56M
Trailing 12 months
Diluted EPS (TTM)
$-49.73
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
-22.8%
Year over year
Net income growth YoY
—
Revenue (TTM)
$31.61M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
-40.6%
Year over year · fewer shares
Revenue CAGR (3Y)
-7.3%
Revenue CAGR (5Y)
+5.1%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
—
Return on assets
-183.2%
Debt / equity
—
Current ratio
0.1
EBITDA (TTM)
−$350.88M
Free cash flow (TTM)
—
Quick ratio
0.1
Interest coverage
-22.2
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$566,000
Total assets
$253.56M
Total debt
—
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$17.09M
Capital expenditures (TTM)
$726,000
R&D (TTM)
$18.61M
SG&A (TTM)
$277.98M
Stock compensation (TTM)
$16.12M
R&D / revenue
58.9%
Stock compensation / revenue
51.0%
Ownership (13F)
9 metrics13F filers
77
13F filer change QoQ
0
Institutional ownership
9.8%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
1.5%
Private-fund adviser ownership
1.5%
Active holders' share change QoQ
-52.5%
Holder tenure
4.4
Price vs estimated holder cost
-87.2%
Ownership (registered funds)
1 metricsIndex-fund ownership
4.1%
Short interest
3 metricsShort interest
1.7%
Latest settlement · 2.6 days to cover
Days to cover
2.6d
Short-squeeze score
35 / 100
Insider activity
2 metricsNet insider buying (90D)
—
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
Flagged
Key facts
CIK
1820190
CUSIP
80880W205
13F (30d)
16 filings
16 filers
Visit website
Investor relations